Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $363 | $154 | $251 | $605 |
| Short-Term Investments | $516 | $696 | $570 | $418 |
| Receivables | $177 | $242 | $292 | $253 |
| Inventory | $205 | $227 | $210 | $180 |
| Other Curr. Assets | $42 | $12 | $14 | $13 |
| Total Curr. Assets | $1,303 | $1,336 | $1,338 | $1,471 |
| Property Plant & Equip (Net) | $218 | $190 | $200 | $206 |
| Goodwill | $17 | $17 | $12 | $7 |
| Intangibles | $0 | $76 | $60 | $20 |
| Long-Term Investments | $458 | $405 | $435 | $557 |
| Tax Assets | $83 | $104 | $125 | $142 |
| Other NC Assets | $82 | $83 | $7 | $4 |
| Total NC Assets | $859 | $799 | $838 | $936 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $2,162 | $2,136 | $2,176 | $2,407 |
| Liabilities | – | – | – | – |
| Payables | $45 | $68 | $68 | $61 |
| Short-Term Debt | $0 | $2 | $2 | $2 |
| Tax Payable | $0 | $33 | $20 | $18 |
| Deferred Revenue | $0 | $1 | $6 | $8 |
| Other Curr. Liab. | $316 | $281 | $336 | $588 |
| Total Curr. Liab. | $361 | $386 | $432 | $676 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $1 | $1 | $1 |
| Deferred Tax Liab, NC | $0 | $19 | $33 | $35 |
| Other NC Liab. | $8 | -$1 | -$1 | -$1 |
| Total NC Liab. | $8 | $19 | $33 | $35 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $369 | $405 | $465 | $711 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,793 | $1 | $1 | $1 |
| Retained Earnings | $0 | $2,414 | $2,389 | $2,339 |
| AOCI | $0 | -$175 | -$169 | -$152 |
| Other Equity | $0 | -$509 | -$509 | -$484 |
| Total Equity | $1,793 | $1,731 | $1,711 | $1,704 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | -$8 |
| Total Liab. & Tot. Equity | $2,162 | $2,136 | $2,176 | $2,407 |
| Net Debt | -$363 | -$153 | -$249 | -$603 |